Research programme: liver disorder therapeutics - CAMP4 Therapeutics
Latest Information Update: 04 Mar 2024
At a glance
- Originator CAMP4 Therapeutics
- Class Antisense oligonucleotides; Hepatoprotectants; Vascular disorder therapies
- Mechanism of Action Complement C1 inhibitor protein expression stimulants; Ornithine carbamoyltransferase expression stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cholangitis; Inborn urea cycle disorders; Ornithine carbamoyltransferase deficiency disease
- Research Hereditary angioedema; Metabolic disorders; Unspecified
Most Recent Events
- 04 Mar 2024 Early research in Metabolic disorders in USA (Parenteral) prior to March 2024 (CAMP4 Therapeutics pipeline, March 2024)
- 04 Mar 2024 Early research in Unspecified in USA (Parenteral) prior to March 2024 (CAMP4 Therapeutics pipeline, March 2024)
- 04 Mar 2024 Preclinical trials in Cholangitis in USA (Parenteral) prior to March 2024 (CAMP4 Therapeutics pipeline, March 2024)